ライフサイエンスコーパス: Holter monitoring

1 and 12 months (as assessed by means of 3-day Holter monitoring).

2 adequacy of MRC was assessed by using serial Holter monitoring.

3 ery 3 to 6 months by clinic review and 7-day Holter monitoring.

4 ticipants did not have at least 1 PAC during Holter monitoring.

5 VT was assessed using Holter monitoring.

6 mia with an event transmitter and ambulatory holter monitoring.

7 den of ectopy was quantified through 24-hour Holter monitoring.

8 puted tomography perfusion scan, and 24-hour Holter monitoring.

9 ocardiography, upright exercise testing, and Holter monitoring.

10 ity of life and for increased arrhythmias by Holter monitoring.

11 re), exercise testing, echocardiography, and Holter monitoring.

12 ause they did not have AECG ischemia on 48-h Holter monitoring.

13 ssion (n = 10 [27%], including by ECG [14%], Holter monitoring [11%], or signal-averaged ECG [14%]) w

14 The duration of ischemia on continuous Holter monitoring after PCI was significantly longer amo

15 AF rhythm control was determined using 7-day Holter monitoring and AF severity scale questionnaire.

16 use of signal-averaged electrocardiography, Holter monitoring and assessment of left ventricular fun

17 rcise tests, exercise thallium scintigraphy, Holter monitoring and electrophysiologic study findings

18 hocardiography, surface electrocardiography, Holter monitoring and exercise testing, when applicable,

19 measured in 60 stable patients after 48-hour Holter monitoring and in 24 matched controls.

20 by assessing heart rate variability on 24-h Holter monitoring and plasma norepinephrine levels durin

21 After ablation, patients underwent repeated Holter monitoring and reassessment of cardiac function.

22 cidence of ineffective capture using 12-lead Holter monitoring and to assess whether this affects res

23 gned to 24-h ambulatory electrocardiography (Holter) monitoring and who had a normal LVEF and no hist

24 al abnormalities (electrocardiography and/or Holter monitoring) and abnormal CMR results.

25 mptoms with documentation, event monitoring, Holter monitoring, and electrocardiograms.

26 , cardiac magnetic resonance imaging (CMRI), Holter monitoring, and exercise testing.

27 ated by 12-lead ECG, echocardiogram, 24-hour Holter monitoring, and laboratory studies.

28 , and cardiac radionuclide ventriculography, Holter monitoring, and polysomnography were done.

29 phy, nonsustained ventricular tachycardia on Holter monitoring, and unexplained prior syncope.

30 ients underwent echocardiography, ambulatory Holter monitoring, and upright exercise testing.

31 aged ECG, exercise testing, cardiac imaging, Holter-monitoring, and selective provocative drug testin

32 rved in laboratory, electrocardiographic, or Holter monitoring assessments.

33 ncreas transplant recipients underwent 24-hr Holter monitoring before and again at 6 and 12 months po

34 Continuous Holter monitoring began immediately before exposure and

35 studies, 12-lead electrocardiograms, 24-hour Holter monitoring, blood tests, and completion of Minnes

36 Recent Holter monitoring data have revealed a high degree of da

37 The maximum reduction in mean heart rate by Holter monitoring during the first 6 h in ozanimod-treat

38 ination, which included electrocardiography, Holter monitoring, echocardiography, bicycle ergometry,

39 cluding ECG, 2-dimensional echocardiography, Holter monitoring, exercise tolerance testing, and ajmal

40 Electrocardiographic and 24-h Holter monitoring findings closest to presentation were

41 on cardiac ultrasonography in 100 of 195, on Holter monitoring in 2 of 192; and on hypercoagulable pa

42 etermined before and after ablation by 7-day Holter monitoring; intermittent ECG event monitoring was

43 verse events at regular scheduled visits and Holter monitoring; key efficacy measures were annualized

44 were evaluated by electrocardiography (ECG), Holter monitoring, late-enhancement cardiac magnetic res

45 Patients with ischemia on Holter monitoring (n=40) received aspirin or placebo in

46 This supports pre-implantation Holter monitoring of patients selected for CRT for optim

47 ties on the basis of electrocardiography and Holter monitoring, of whom 20 (48%) had abnormal results

48 s in patients with organic heart disease, 2) Holter monitoring or telemetry in patients known to have

49 Holter monitoring, or intracardiac electrophysiologic st

50 MCSF was related to ischemia on Holter monitoring (P<0.01), to low ischemic threshold du

51 cal abnormalities on electrocardiography and Holter monitoring precede detectable structural abnormal

52 Patients underwent 48-h electrocardiographic Holter monitoring quarterly to detect brief subclinical

53 Holter monitoring revealed ST elevation during chest pai

54 In vivo, Holter monitoring revealed ventricular arrhythmias and S

55 Electrocardiograms and 24-h Holter monitoring showed no increased incidence of atrio

56 were evaluated by electrocardiography (ECG), Holter monitoring, signal-averaged ECG, and cardiac magn

57 During Holter monitoring, the sensitivity of the detection of A

58 Holter monitoring was performed for 4.8+/-1.4 days after

59 y drug was continued for 24 to 72 hours, and Holter monitoring was performed.

60 d corrected QT intervals were recorded; 24 h Holter monitoring was utilized to gauge efficacy of trea

61 The clinical course, electrocardiograms, and Holter monitoring were available for review in 114 subje

62 aphy (SPECT) perfusion scanning, and 24-hour Holter monitoring were performed at baseline and follow-

63 ECG and 24-hour Holter monitoring were performed biweekly.

64 axar significantly reduced early ischemia on Holter monitoring without a significant increase in majo